Velaglucerase alfa (Vpriv)

Vpriv (velaglucerase alfa) is covered only for the FDA‑approved indication of Type 1 Gaucher disease and no off‑label/compendial uses are approved. Approval requires documented β‑glucocerebrosidase deficiency or GBA gene mutation, prescription by or consultation with an appropriate specialist (geneticist, endocrinologist, metabolic/lysosomal disorder specialist), dosing of 60 U/kg IV no more frequently than every 2 weeks, a 1‑year authorization, and submission of lab/genetic results, prescriber specialty/consultation note, and clinical records.

"Vpriv is indicated for the treatment of individuals with Type 1 Gaucher disease."

Sign up to see full coverage criteria, indications, and limitations.